Axial: https://linktr.ee/axialxyz
Axial partners with great founders and inventors. We invest in early-stage life sciences companies such as Appia Bio, Seranova Bio, Delix Therapeutics, Simcha Therapeutics, among others often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company. We are excited to be in business with you — email us at info@axialvc.com
Paul Janssen was a pioneering Belgian physician and pharmaceutical researcher who founded the company Janssen Pharmaceutica. Through his intense focus, creativity, and systematic approach to drug discovery, Janssen developed over 100 transformative medicines that improved the lives of millions worldwide.
Paul Janssen was born in 1926 in Turnhout, Belgium. From a young age, he was inspired by science and medicine. His father, Constant Janssen, was a general practitioner who in 1933 expanded into the pharmaceutical business by acquiring rights to distribute drugs from a Hungarian company in Belgium and the Dutch colonies.
As a teenager during World War II, Paul studied science at a Catholic school. He was struck by the importance of chemistry for advancing medicine. In 1945, Janssen began medical studies at the Catholic University of Leuven, but took a break in 1948 to travel the United States learning about pharmacology research. He was especially intrigued by the prospect of synthesizing new chemical compounds to achieve desired pharmacological effects. After returning and finishing his medical degree in 1951, Janssen fulfilled his military service in Germany. There, he continued independent studies in pharmacology and chemistry at the University of Cologne while serving as a part-time teaching assistant. In 1956, he earned his PhD in pharmacology from Ghent University under renowned Nobel laureate Corneel Heymans.
Rather than pursuing an academic career, Janssen was eager to launch his own independent laboratory for pharmaceutical research. In 1953, he set up a small lab in his parents’ company building in Turnhout. His goal was to secure patents on original drug compounds that could generate licensing revenue to fund further research.
Janssen’s focus was on elucidating the chemical structures responsible for a drug’s effects on the body. By modifying molecular structures, he could then predict and control biological activity. This iterative, systematic approach followed the traditions of pioneers like Paul Ehrlich and Daniel Bovet in exploring chemical “drug space” for new medicines. In 1955, Janssen’s group synthesized ambucetamide, their first commercial drug for menstrual pain relief. Over the next decade, the lab expanded and discovered important compounds like the antipsychotic haloperidol (1958) and the potent anesthetic fentanyl (1963). The promise of Janssen’s discoveries attracted the attention of Johnson & Johnson, who acquired his company in 1961 while allowing continuation of independent research.
Janssen approached drug discovery like an evolutionary process. It started with a lead compound targeted to a disease based on some biological rationale. Then, hundreds of analogs would be synthesized and tested in animal models, mapping out structure activity relationships. Promising leads were followed up with further rounds of optimization. Like natural selection, this iterative trial-and-error helped guide the molecule toward higher “fitness” as a drug.
Success required intense concentration to track all the data and make judgments about new directions. It also demanded complete commitment to see each project through the long, gradual process toward fruition rather than flitting from target to target. Janssen was known for exemplary focus and persistence once he locked onto a new concept. Janssen also displayed great creativity and intuition, knowing when a molecule was “fit” for clinical use. He was able to envision how chemical structures related to potential therapeutic effects, filling his mind with “pharmacophores” that guided his designs. Janssen generated over 100 patents and discovered new medicines across nearly every clinical field, including mental illness, pain, infections, gastroenterology, cardiology, and oncology.
Some notable drugs included:
- Loperamide: antidiarrheal medication based on modification of the opioid pethidine. Loperamide provided relief of diarrhea symptoms without the addiction potential.
- Risperidone: an atypical antipsychotic with fewer side effects. It became a widely used treatment for schizophrenia and bipolar disorder.
- Mebendazole: brought forward a class of benzimidazole drugs that were effective against common intestinal worms and other parasites.
- Etoricoxib: a Cox-2 inhibitor anti-inflammatory medication for arthritis, similar to celecoxib.
- Pimozide: early antipsychotic for Tourette syndrome marked by reduced neuromuscular side effects.
- Oxatomide: antiallergic drug that inhibits histamine release. Used for treatment of hay fever and allergic skin conditions.
- Ketoconazole: antifungal drug effective against serious infections like blastomycosis and candidiasis.
Janssen Pharmaceutica experienced tremendous growth under Paul Janssen’s leadership, expanding to over 40 international affiliates and 23K employees. He stepped back from daily operations in the 1990s but remained an active advisor. At age 75, he still displayed anger at high drug development costs that prevented important therapies for rare diseases from being pursued.
Janssen authored over 850 scientific publications over his career. He garnered numerous honors including 80+ medical awards and 22 honorary doctorates. However, despite being nominated many times, he was never awarded a Nobel Prize. Some believed his discoveries were too numerous to be easily encapsulated for the award. Colleagues described Janssen as highly motivating and generous toward his staff, but also demanding results and excellence. His intense drive was credited as the key force behind his productivity, setting the culture for his organization. Janssen led by example, putting in long hours in the lab himself and synthesizing compounds over the weekends. However, he also knew how to delegate and build an outstanding team around him.
Above all, Paul Janssen will be remembered for his insatiable curiosity, creativity, and perseverance as a drug hunter. He pioneered new classes of life-saving medications across infectious disease, psychiatry, pain management, and more. Even 50 years after its founding, the research institute Janssen created continues making important medical advances that improve patient health and wellbeing worldwide. When reflecting on his legacy, Janssen remarked “I am happy knowing that our research has led to the improvement of patient care.” Through his life's work, Paul Janssen exemplified the power of bold scientific exploration, systematic rigor, and commitment to medical progress.
